Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MGLL | Q99685 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL95521 | 0.78 | LMNA (0.42) | SMN1; SMN2MAPTHPGDMGLLHSD17B10 | |
| SCHEMBL1713865 | 0.75 | SMN1; SMN2 (0.50) | SMN1; SMN2MAPTHPGDMGLLHSD17B10 | |
| SCHEMBL9601062 | 0.72 | ALDH1A1 (0.44) | SMN1; SMN2MAPTHPGDMGLLHSD17B10 | |
| SCHEMBL10399871 | 0.72 | MAOA (0.41) | SMN1; SMN2MAPTHPGDMGLLHSD17B10 | |
| SCHEMBL777177 | 0.71 | SMN1; SMN2 (0.46) | SMN1; SMN2MAPTHPGDMGLLHSD17B10 | |
| SCHEMBL13901175 | 0.71 | MAPT (0.45) | SMN1; SMN2MAPTHPGDMGLLHSD17B10 | |
| SCHEMBL3911663 | 0.71 | SMN1; SMN2 (0.45) | SMN1; SMN2MAPTHPGDMGLLHSD17B10 | |
| SCHEMBL343269 | 0.71 | SMN1; SMN2 (0.45) | SMN1; SMN2MAPTHPGDMGLLHSD17B10 | |
| SCHEMBL1453001 | 0.71 | SMN1; SMN2 (0.45) | SMN1; SMN2MAPTHPGDMGLLHSD17B10 | |
| SCHEMBL5173197 | 0.71 | SMN1; SMN2 (0.45) | SMN1; SMN2MAPTHPGDMGLLHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110209699-A1 | COMBINATION OF DEHYDROEPIANDROSTERONE OR DEHYDROEPIANDROSTERONE-SULFATE WITH A LIPOXYGENASE INHIBITOR FOR TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE | EPIGENESIS PHARMACEUTICALS, LLC | 2011-09-01 | — | — | US | disclosed |
| EP-1954320-A2 | COMPOSITIONS COMPRISING LIPOXYGENASE INHIBITORS AND CYCLODEXTRIN | Baxter International Inc. (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1954245-A2 | COMPOSITIONS OF LIPOXYGENASE INHIBITORS | Baxter International Inc. (US) | 2008-08-13 | — | — | EP | disclosed |
| US-20070134341-A1 | COMPOSITIONS OF LIPOXYGENASE INHIBITORS | BAXTER INTERNATIONAL INC. | 2007-06-14 | — | — | US | disclosed |
| WO-2007059515-A2 | COMPOSITIONS OF LIPOXYGENASE INHIBITORS | BAXTER INTERNATIONAL, INC. (US) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007059507-A2 | COMPOSITIONS COMPRISING LIPOXYGENASE INHIBITORS AND CYCLODEXTRIN | BAXTER INTERNATIONAL, INC. (US) | 2007-05-24 | — | — | WO | disclosed |
| US-20070111965-A1 | COMPOSITIONS COMPRISING LIPOXYGENASE INHIBITORS AND CYCLODEXTRIN | BAXTER HEALTHCARE S.A. (CH) | 2007-05-17 | — | — | US | disclosed |
| US-20050090455-A1 | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease | EPIGENESIS PHARMACEUTICALS, LLC. | 2005-04-28 | — | — | US | disclosed |
| US-20050043282-A1 | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease | EPIGENESIS PHARMACEUTICALS LLC | 2005-02-24 | — | — | US | disclosed |
| WO-2005011613-A2 | COMBINATION OF DEHYDROEPIANDROSTERONE OR DEHYDROEPIANDROSTERONE-SULFATE WITH A LIPOXYGENASE INHIBITOR FOR TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE | EPIGENESIS PHARMACEUTICALS LLC (US) | 2005-02-10 | — | — | WO | disclosed |
| EP-0388429-A1 | FURAN AND PYRROLE CONTAINING LIPOXYGENASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 1990-09-26 | — | — | EP | disclosed |
| WO-1989012636-A1 | TRICYCLIC LIPOXYGENASE INHIBITING COMPOUNDS, COMPOSITIONS, METHODS OF USE | ABBOTT LABORATORIES (US) | 1989-12-28 | — | — | WO | disclosed |
| EP-0346939-A1 | Tricyclic lipoxygenase inhibiting compounds | ABBOTT LABORATORIES (US) | 1989-12-20 | — | — | EP | disclosed |
| US-4873259-A | Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting compounds | ABBOTT LABORATORIES (US) | 1989-10-10 | — | — | US | disclosed |
| EP-0320628-A1 | Substituted furan compounds which are useful in inhibiting lipoxygenase enzymes, particularly 5-lipoxygenase | ABBOTT LABORATORIES (US) | 1989-06-21 | — | — | EP | disclosed |
| WO-1989004299-A1 | FURAN AND PYRROLE CONTAINING LIPOXYGENASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 1989-05-18 | — | — | WO | disclosed |
| US-4822811-A | Carbazole lipoxygenase inhibiting compounds, compositions and use | ABBOTT LABORATORIES (US) | 1989-04-18 | — | — | US | disclosed |
| US-4822809-A | ENZYME INHIBITORS | ABBOTT LABORATORIES (US) | 1989-04-18 | — | — | US | disclosed |
| US-4769387-A | Dibenzofuran lipoxygenase inhibiting compounds, compositions and use | ABBOTT LABORATORIES (US) | 1988-09-06 | — | — | US | disclosed |
| EP-0279263-A2 | Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting compounds | ABBOTT LABORATORIES (US) | 1988-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111965-A1 | COMPOSITIONS COMPRISING LIPOXYGENASE INHIBITORS AND CYCLODEXTRIN | ALOX15B, ALOX12, ALOX15 | SMN1; SMN2 2283/4885MAPT 3925/4885HPGD 61/4885 |
| US-20050090455-A1 | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease | HSD11B2, CYP17A1, ALOX5 | SMN1; SMN2 4308/4885MAPT 4788/4885HPGD 38/4885 |
| US-20050043282-A1 | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease | HSD11B2, CYP17A1, ALOX5 | SMN1; SMN2 4270/4885MAPT 4795/4885HPGD 37/4885 |
| US-20070134341-A1 | COMPOSITIONS OF LIPOXYGENASE INHIBITORS | ALOX5, ALOX15B, ALOX15 | SMN1; SMN2 3416/4885MAPT 3925/4885HPGD 85/4885 |
| US-20110209699-A1 | COMBINATION OF DEHYDROEPIANDROSTERONE OR DEHYDROEPIANDROSTERONE-SULFATE WITH A LIPOXYGENASE INHIBITOR FOR TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE | HSD11B2, CYP17A1, ALOX5 | SMN1; SMN2 4308/4885MAPT 4788/4885HPGD 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.